Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1989 Jan;96(1):211–219. doi: 10.1111/j.1476-5381.1989.tb11802.x

1,3,8- and 1,3,7-substituted xanthines: relative potency as adenosine receptor antagonists at the frog neuromuscular junction.

A M Sebastião 1, J A Ribeiro 1
PMCID: PMC1854313  PMID: 2924073

Abstract

1. The ability of 1,3,8-substituted xanthines (1,3-dipropyl-8-(4-(2-aminoethyl)amino)carbonylmethyloxyphenyl) xan thine (XAC), 1,3-dipropyl-8-(4-carboxymethyloxyphenyl)xanthine (XCC), 1,3-dipropyl-8-(2-amino-4-chlorophenyl)xanthine (PACPX), 1,3-dipropyl-8-cyclopentylxanthine (DPCPX), 1,3-diethyl-8-phenylxanthine (DPX) and 8-phenyltheophylline (8-PT)), of 1,3,7-substituted xanthines (1-propargyl-3,7-dimethylxanthine (PGDMX) and caffeine), and of a 3-substituted xanthine (enprofylline) to antagonize the inhibitory effect of 2-chloroadenosine (CADO) on the amplitude of nerve-evoked twitches was investigated in innervated sartorius muscles of the frog. 2. All the 1,3,8-substituted xanthines, in concentrations virtually devoid of effect on neuromuscular transmission, shifted to the right, in a near parallel manner the log concentration-response curve for CADO. Linear Schild plots with slopes near to unity at concentration-ratios less than 14 were obtained for XAC, XCC, DPCPX, DPX and 8-PT. 3. The order of potency of the 1,3,8-substituted xanthines as antagonists of the effect of CADO was XAC (Ki = 23 nM) greater than or equal to DPCPX (35 nM) greater than 8-PT (200 nM) greater than or equal to DPX (295 nM) greater than XCC (1905 nM) greater than or equal to PACPX (2291 nM). No correlation was found between the potency of these xanthines as antagonists of the adenosine receptor at the frog neuromuscular junction and their reported potency as antagonists of the A1- or A2-adenosine receptors. 4. The 1,3,7-substituted xanthines, PGDMX and caffeine, in concentrations virtually devoid of effect on neuromuscular transmission, also caused parallel shifts to the right of the log concentration-response curves for CADO, but were less potent than the 1,3,8-substituted xanthines. PGDMX was more than 20 times more potent than caffeine. 5. Enprofylline in concentrations up to 100 microM did not antagonize the inhibitory effect of CADO on neuromuscular transmission. 6. It is concluded that the antagonist profile of the adenosine receptor mediating inhibition of transmission at the frog neuromuscular junction is different from the antagonist profile of the A1- and A2-adenosine receptors.

Full text

PDF
211

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ARUNLAKSHANA O., SCHILD H. O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother. 1959 Mar;14(1):48–58. doi: 10.1111/j.1476-5381.1959.tb00928.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bruns R. F. Adenosine antagonism by purines, pteridines and benzopteridines in human fibroblasts. Biochem Pharmacol. 1981 Feb 15;30(4):325–333. doi: 10.1016/0006-2952(81)90062-9. [DOI] [PubMed] [Google Scholar]
  3. Bruns R. F., Daly J. W., Snyder S. H. Adenosine receptor binding: structure-activity analysis generates extremely potent xanthine antagonists. Proc Natl Acad Sci U S A. 1983 Apr;80(7):2077–2080. doi: 10.1073/pnas.80.7.2077. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Burnstock G., Hoyle C. H. PACPX--a substituted xanthine--antagonizes both the A1 and A2 subclasses of the P1-purinoceptor: antagonism of the A2 subclass is competitive but antagonism of the A1 subclass is not. Br J Pharmacol. 1985 May;85(1):291–296. doi: 10.1111/j.1476-5381.1985.tb08859.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Collis M. G., Jacobson K. A., Tomkins D. M. Apparent affinity of some 8-phenyl-substituted xanthines at adenosine receptors in guinea-pig aorta and atria. Br J Pharmacol. 1987 Sep;92(1):69–75. doi: 10.1111/j.1476-5381.1987.tb11297.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Daly J. W., Bruns R. F., Snyder S. H. Adenosine receptors in the central nervous system: relationship to the central actions of methylxanthines. Life Sci. 1981 May 11;28(19):2083–2097. doi: 10.1016/0024-3205(81)90614-7. [DOI] [PubMed] [Google Scholar]
  7. Lohse M. J., Klotz K. N., Lindenborn-Fotinos J., Reddington M., Schwabe U., Olsson R. A. 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1987 Aug;336(2):204–210. doi: 10.1007/BF00165806. [DOI] [PubMed] [Google Scholar]
  8. Londos C., Cooper D. M., Wolff J. Subclasses of external adenosine receptors. Proc Natl Acad Sci U S A. 1980 May;77(5):2551–2554. doi: 10.1073/pnas.77.5.2551. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Martinson E. A., Johnson R. A., Wells J. N. Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. Mol Pharmacol. 1987 Mar;31(3):247–252. [PubMed] [Google Scholar]
  10. Persson C. G., Andersson K. E., Kjellin G. Effects of enprofylline and theophylline may show the role of adenosine. Life Sci. 1986 Mar 24;38(12):1057–1072. doi: 10.1016/0024-3205(86)90241-9. [DOI] [PubMed] [Google Scholar]
  11. Ribeiro J. A., Sebastião A. M. Adenosine receptors and calcium: basis for proposing a third (A3) adenosine receptor. Prog Neurobiol. 1986;26(3):179–209. doi: 10.1016/0301-0082(86)90015-8. [DOI] [PubMed] [Google Scholar]
  12. Ribeiro J. A., Sebastião A. M. On the role, inactivation and origin of endogenous adenosine at the frog neuromuscular junction. J Physiol. 1987 Mar;384:571–585. doi: 10.1113/jphysiol.1987.sp016470. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ribeiro J. A., Sebastião A. M. On the type of receptor involved in the inhibitory action of adenosine at the neuromuscular junction. Br J Pharmacol. 1985 Apr;84(4):911–918. doi: 10.1111/j.1476-5381.1985.tb17385.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Schwabe U., Ukena D., Lohse M. J. Xanthine derivatives as antagonists at A1 and A2 adenosine receptors. Naunyn Schmiedebergs Arch Pharmacol. 1985 Sep;330(3):212–221. doi: 10.1007/BF00572436. [DOI] [PubMed] [Google Scholar]
  15. Sebastião A. M., Ribeiro J. A. On the adenosine receptor and adenosine inactivation at the rat diaphragm neuromuscular junction. Br J Pharmacol. 1988 May;94(1):109–120. doi: 10.1111/j.1476-5381.1988.tb11505.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Silinsky E. M. Evidence for specific adenosine receptors at cholinergic nerve endings. Br J Pharmacol. 1980;71(1):191–194. doi: 10.1111/j.1476-5381.1980.tb10925.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Ukena D., Daly J. W., Kirk K. L., Jacobson K. A. Functionalized congeners of 1,3-dipropyl-8-phenylxanthine: potent antagonists for adenosine receptors that modulate membrane adenylate cyclase in pheochromocytoma cells, platelets and fat cells. Life Sci. 1986 Mar 3;38(9):797–807. doi: 10.1016/0024-3205(86)90596-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Ukena D., Jacobson K. A., Padgett W. L., Ayala C., Shamim M. T., Kirk K. L., Olsson R. O., Daly J. W. Species differences in structure-activity relationships of adenosine agonists and xanthine antagonists at brain A1 adenosine receptors. FEBS Lett. 1986 Dec 1;209(1):122–128. doi: 10.1016/0014-5793(86)81096-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Ukena D., Schirren C. G., Schwabe U. Effects of enprofylline on A1 and A2 adenosine receptors. Eur J Pharmacol. 1985 Oct 29;117(1):25–33. doi: 10.1016/0014-2999(85)90468-6. [DOI] [PubMed] [Google Scholar]
  20. Ukena D., Shamim M. T., Padgett W., Daly J. W. Analogs of caffeine: antagonists with selectivity for A2 adenosine receptors. Life Sci. 1986 Aug 25;39(8):743–750. doi: 10.1016/0024-3205(86)90023-8. [DOI] [PubMed] [Google Scholar]
  21. Williams M., Jarvis M. F., Sills M. A., Ferkany J. W., Braunwalder A. Biochemical characterization of the antagonist actions of the xanthines, PACPX (1,3-dipropyl-8(2-amino-4-chloro)phenylxanthine) and 8-PT (8-phenyltheophylline) at adenosine A1 and A2 receptors in rat brain tissue. Biochem Pharmacol. 1987 Nov 15;36(22):4024–4027. doi: 10.1016/0006-2952(87)90476-x. [DOI] [PubMed] [Google Scholar]
  22. van Calker D., Müller M., Hamprecht B. Adenosine regulates via two different types of receptors, the accumulation of cyclic AMP in cultured brain cells. J Neurochem. 1979 Nov;33(5):999–1005. doi: 10.1111/j.1471-4159.1979.tb05236.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES